Bicycle Therapeutics plc
NASDAQ:BCYCBiotechnology
-$0.06 today
- Market cap
- $217.99M
- Beta
- 1.54
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$3.14
Volume 0.57M
Average 0.49M
BCYC Total Debt
Short-term and long-term borrowings combined.
Bicycle Therapeutics plcNASDAQ: BCYC
Total Debt · Q1 FY2026 · quarter ended Mar 2026
Total debt rises 68.2% from a year ago
Total debt stood at $15.34M at the end of Q1 FY2026, up 68.2% from a year earlier and down 12.5% from the prior quarter. Over 3 fiscal years it compounded at -26.6% a year.
Context
- Total debt amounted to 2.4% of total assets at the end of Q1 FY2026, up 1.3 pp from a year earlier.
- Total debt increased in 2 of the last 3 fiscal years.
What to watch
Whether total debt keeps rising in the next quarterly balance sheet after a +68.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 17.52M USD
- Year-over-year change
- +84.6%
- 4-year CAGR
- -20.7%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.52M | +84.6% |
| FY2024 | 2024-12-31 | 9.49M | -78.9% |
| FY2023 | 2023-12-31 | 44.96M | +1.4% |
| FY2022 | 2022-12-31 | 44.33M | -0.0% |
| FY2021 | 2021-12-31 | 44.34M | — |
Total Debt vs competitors
How BCYC compares with its peers on the latest reported figures
- BCYC's Mar 2026 total debt of $15.34M is the 6th highest of the 10 companies compared; the peer median is $20.54M.
- Its year-over-year change of +68.2% is the highest of 9, against a peer median of -26.4%.
- Total debt amounts to 2.4% of total assets for BCYC, versus a peer median of 4.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $310.63M | -25.2% | -11.2% | 108.5% | |
| Dec 2025 | $151.58M | — | — | 45.2% | |
| Mar 2026 | $116.67M | -74.1% | +50.1% | 40.0% | |
| Mar 2026 | $57.71M | -45.7% | +4.0% | 21.5% | |
| Mar 2026 | $20.54M | -13.9% | +9.9% | 4.0% | |
| Mar 2026 | $15.34M | +68.2% | -26.6% | 2.4% | |
| Mar 2026 | $9.79M | +53.4% | +49.6% | 4.8% | |
| Mar 2026 | $7.65M | -25.0% | +28.9% | 2.2% | |
| Mar 2026 | $5.87M | -27.6% | -21.7% | 1.7% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $410K | -56.3% | -61.6% | 0.3% |
| Peer median (excluding BCYC) | $20.54M | -26.4% | +7.0% | 4.8% | |
Competitors are the stored peer set for BCYC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 438.68M | 339.15M | 526.42M | 879.52M | 628.11M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 11.91M | 21.21M | 24.04M | 35.65M | 35.59M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 7.97M | 9.02M | 11.41M | 13.43M | (35.59M) |
| Total Current Assets | 458.56M | 369.38M | 561.87M | 928.61M | 628.11M |
| Property, Plant & Equipment (Net) | 17.79M | 32.77M | 27.68M | 17.19M | 21.91M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 547K | 547K | 58K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.45M | 8.46M | 5.24M | 10.53M | 12.75M |
| Total Non-current Assets | 21.24M | 41.23M | 33.48M | 28.26M | 34.71M |
| Total Assets | 479.79M | 410.61M | 595.34M | 956.87M | 717.6M |
| Account Payables | 2.72M | 6.47M | 13.05M | 15.79M | 9.67M |
| Short-term Debt | 0 | 0 | 4.88M | 0 | 2.76M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 19.27M | 20.42M | 24.98M | 10.19M | 2.96M |
| Other Current Liabilities | 7M | 13.4M | 13.24M | 16.57M | 17.14M |
| Total Current Liabilities | 36.24M | 53.34M | 69.54M | 67.23M | 56.98M |
| Long-term Debt | 29.87M | 30.32M | 30.7M | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 52.07M | 41.46M | 110.22M | 91.47M | 35.51M |
| Other Non-current Liabilities | 3.28M | 3.83M | 4.58M | 1.12M | 363K |
| Total Non-current Liabilities | 97.3M | 86.48M | 154.88M | 96.58M | 50.64M |
| Total Liabilities | 133.54M | 139.83M | 224.41M | 163.81M | 107.62M |
| Common Stock | 384K | 387K | 550K | 890K | 894K |
| Retained Earnings | (218.38M) | (331.1M) | (511.76M) | (680.79M) | (899.75M) |
| Accumulated OCI | (3.39M) | 387K | (1.3M) | 119K | (3.51M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 346.25M | 270.78M | 370.93M | 793.06M | 609.98M |
| Total Debt | 44.34M | 44.33M | 44.96M | 9.49M | 17.52M |
| Net Debt | (394.34M) | (294.83M) | (481.47M) | (870.03M) | (610.59M) |
Bicycle Therapeutics plc
NASDAQ:BCYC
Intrinsic Alpha fair value
Locked
Current Price
$3.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.